Floatz logo

il-15

T-Cell Prolymphocytic Leukemia

National Cancer Institute (NCI)Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the T-Cell Prolymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 2BB
Fludarabine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB

View all 29 →

Same molecule, other indications

il-15 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
leukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →